The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do both better or worse than that. Unfortunately the Urovo Technology Co., Ltd. (SZSE:300531) share price slid 37% over twelve months. That's well below the market decline of 18%. Longer term shareholders haven't suffered as badly, since the stock is down a comparatively less painful 17% in three years. On top of that, the share price is down 11% in the last week.
If the past week is anything to go by, investor sentiment for Urovo Technology isn't positive, so let's see if there's a mismatch between fundamentals and the share price.
Check out our latest analysis for Urovo Technology
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
During the unfortunate twelve months during which the Urovo Technology share price fell, it actually saw its earnings per share (EPS) improve by 8.6%. It's quite possible that growth expectations may have been unreasonable in the past.
The divergence between the EPS and the share price is quite notable, during the year. But we might find some different metrics explain the share price movements better.
Given the yield is quite low, at 0.4%, we doubt the dividend can shed much light on the share price. Revenue was fairly steady year on year, which isn't usually such a bad thing. But the share price might be lower because the market expected a meaningful improvement, and got none.
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
![earnings-and-revenue-growth](https://usnewsfile.futunn.com/pic/0-17209325-0-09fefe205640718dcbce9e39f0c478be.png/big)
SZSE:300531 Earnings and Revenue Growth November 28th 2022
If you are thinking of buying or selling Urovo Technology stock, you should check out this FREE detailed report on its balance sheet.
A Different Perspective
We regret to report that Urovo Technology shareholders are down 37% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 18%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 4% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. Before forming an opinion on Urovo Technology you might want to consider these 3 valuation metrics.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on CN exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
从上涨的市场中获益的最简单方式是购买指数基金。但如果你买入个股,你可以做得更好,也可以做得更差。不幸的是,乌罗沃科技有限公司。(SZSE:300531)股价在12个月内下滑了37%。这远低于市场18%的跌幅。较长期股东的损失没有那么严重,因为该股在三年内下跌了17%,跌幅相对较小。最重要的是,该公司股价在过去一周下跌了11%。
如果以过去一周为标准,投资者对Urovo Technology的情绪并不乐观,所以让我们看看基本面和股价之间是否存在错配。
查看我们对Urovo Technology的最新分析
虽然有效市场假说继续被一些人传授,但事实证明,市场是过度反应的动态系统,投资者并不总是理性的。通过比较每股收益(EPS)和股价随时间的变化,我们可以感受到投资者对一家公司的态度随着时间的推移发生了怎样的变化。
不幸的是,在Urovo科技股价下跌的12个月里,它的每股收益(EPS)实际上提高了8.6%。过去的增长预期很有可能是不合理的。
在这一年中,每股收益和股价之间的背离相当明显。但我们可能会发现一些不同的衡量标准可以更好地解释股价走势。
鉴于收益率相当低,只有0.4%,我们怀疑股息能否对股价产生太大影响。营收与去年同期相比相当稳定,这通常不是一件坏事。但股价可能会更低,因为市场预计会出现有意义的改善,但没有得到任何改善。
您可以在下图中看到收益和收入随时间的变化(单击图表查看确切的值)。
![earnings-and-revenue-growth](https://usnewsfile.futunn.com/pic/0-17209325-0-09fefe205640718dcbce9e39f0c478be.png/big)
深圳证交所:300531收益和收入增长2022年11月28日
如果你正在考虑购买或出售Urovo科技的股票,你应该看看这个免费关于其资产负债表的详细报告。
不同的视角
我们遗憾地报告,Urovo Technology的股东今年以来下降了37%(甚至包括股息)。不幸的是,这比大盘18%的跌幅还要糟糕。话虽如此,在下跌的市场中,一些股票不可避免地会被超卖。关键是要密切关注基本面的发展。不幸的是,去年的表现可能预示着尚未解决的挑战,因为它比过去五年4%的年化损失更糟糕。我们意识到,罗斯柴尔德男爵曾说过,投资者应该“在街上血淋淋的时候买入”,但我们警告投资者,首先应该确保他们购买的是一家高质量的企业。在对Urovo Technology形成看法之前,您可能需要考虑以下三个估值指标。
如果你更愿意看看另一家公司--一家财务状况可能更好的公司--那么不要错过这一点免费已证明自己能够实现盈利增长的公司名单。
请注意,本文引用的市场回报反映了目前在CN交易所交易的股票的市场加权平均回报。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。